TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01967732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own conventional cigarette (CC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own conventional cigarette (CC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NNS
Description: Single administration of 1 mg of nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NNS
Description: Single administration of 1 mg of nicotine
Study: NCT00701038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto adjusting bi-level positive airway pressure device
Description: auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
Study: NCT01760850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Engage in the Esperanza y Vida educational information session for breast and cervical cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Engage in an educational information session for diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03536000

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography using the aCMQ-Strain method
Description: Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography using the aCMQ-Strain method
Description: Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography using the aCMQ-Strain method
Description: Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography using the aCMQ-Strain method
Description: Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
Study: NCT03598413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
Study: NCT02008721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGCG as putative neuroprotective agent
Description: Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02652988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active home-based tDCS applied at home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham home-based tDCS applied at home.
Study: NCT00935376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Program
Description: Treatment as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Program
Description: Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
Study: NCT00232492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo males
Description: Intravenous saline bolus (Placebo-control) males
Study: NCT02410512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
Description: Atezolizumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
Description: Atezolizumab will be administered intravenously.
Study: NCT00232492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,1 mg/kg males
Description: 0,1 mg/kg ketamine iv bolus males

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,3 mg/kg males
Description: 0,3 mg/kg ketamine iv bolus males
Study: NCT04483960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Tinzaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Tinzaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (Arm Never Opened) Hyperimmune globulin
Description: 2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
Study: NCT00232492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,5 mg/kg males
Description: 0,5 mg/kg ketamine iv bolus males

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo females
Description: Intravenous saline bolus (Placebo-control) females

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,1 mg/kg females
Description: 0,1 mg/kg iv bolus ketamine females
Study: NCT04483960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-Ritonavir
Description: The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
Study: NCT00232492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,3 mg/kg females
Description: 0,3 mg/kg iv bolus ketamine females

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0,5 mg/kg females
Description: 0,5 mg/kg iv bolus ketamine females
Study: NCT00762320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Kaletra tablets
Description: Lopinavir/Ritonavir tablets 100mg/25mg
Study: NCT02712034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAT + A-CHESS
Description: Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MAT
Description: Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care.
Study: NCT00801008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and relaxation intervention
Description: Comparison of an exercise and relaxation intervention to a wait-list control condition

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise and relaxation intervention
Description: Comparison of an exercise and relaxation intervention to a wait-list control condition
Study: NCT01492075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCRA (Intermittent injection)
Description: Intermittent injection of LA intraabdominally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCRA (Intermittent injection)
Description: Intermittent injection of LA intraabdominally
Study: NCT04483960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-Ritonavir
Description: The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
Study: NCT01625221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Anal Sphincter
Description: The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
Study: NCT01263834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Study: NCT01647490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Cardiac Pacemaker Implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permanent Cardiac Pacemaker Implantation
Study: NCT01355393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID
Study: NCT04483960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
Study: NCT04349345

Intervention type: DIAGNOSTIC_TEST
Intervention: sperm count
Description: total progressive sperm motile count
Study: NCT01355393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID
Study: NCT00932373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-MCC-DM1
Description: Intravenous escalating dose
Study: NCT01835873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Study: NCT01355393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID
Study: NCT02410512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
Description: MOXR0916 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
Description: MOXR0916 will be administered intravenously.
Study: NCT03243539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Protective Ventilation
Description: Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
Study: NCT05236946

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery/whole brain radiotherapy
Description: SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: TKI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine kinase inhibitor
Description: TKI
Study: NCT03907995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
Study: NCT04088019

Intervention type: DRUG
Intervention: Fixed drug combination (FDC) of ATT and Oral steroid
Description: In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks.
Study: NCT03923933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Chlorthalidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bumetanide
Description: Bumetanide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide
Study: NCT04582474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dengue module and rapid diagnostic tests
Description: Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
Study: NCT03942133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal
Description: Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided long-axis placement of catheter at the middle of the adductor canal
Description: Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
Study: NCT02794376

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Cognitive Therapy (MBCT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting Period
Study: NCT04983381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia education video
Description: The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
Study: NCT04080050

Intervention type: DRUG
Intervention: Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
Description: No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
Study: NCT04523896

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy
Description: - Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian).
Study: NCT03167307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
Study: NCT02454101

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cord milking
Description: milking of the cord 5 times toward the neonate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: delayed cord clamping
Description: delay clamping of the cord for 120 seconds
Study: NCT04073238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Red-light Therapy
Description: In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
Study: NCT01835873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES 130/0.42
Description: Balanced colloid solution
Study: NCT03818282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
Study: NCT01206998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Description: Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
Study: NCT02275065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Bictegravir tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Bictegravir tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Bictegravir tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Bictegravir tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match bictegravir administered orally once daily
Study: NCT02495051

Intervention type: PROCEDURE
Intervention: esophageal biopsies